'Gain' of supernumerary copies of the 8q24. 21 chromosomal region has been shown to be common in many human cancers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and is associated with poor prognosis 7, 10, 14 . The well-characterized myelocytomatosis (MYC) oncogene resides in the 8q24.21 region and is consistently co-gained with an adjacent 'gene desert' of approximately 2 megabases that contains the long non-coding RNA gene PVT1, the CCDC26 gene candidate and the GSDMC gene. Whether low copynumber gain of one or more of these genes drives neoplasia is not known. Here we use chromosome engineering in mice to show that a single extra copy of either the Myc gene or the region encompassing Pvt1, Ccdc26 and Gsdmc fails to advance cancer measurably, whereas a single supernumerary segment encompassing all four genes successfully promotes cancer. Gain of PVT1 long non-coding RNA expression was required for high MYC protein levels in 8q24-amplified human cancer cells. PVT1 RNA and MYC protein expression correlated in primary human tumours, and copy number of PVT1 was co-increased in more than 98% of MYC-copy-increase cancers. Ablation of PVT1 from MYC-driven colon cancer line HCT116 diminished its tumorigenic potency. As MYC protein has been refractory to small-molecule inhibition, the dependence of high MYC protein levels on PVT1 long non-coding RNA provides a much needed therapeutic target.
To determine whether low copy-number gain of MYC and/or other genetic element(s) in the 8q24.21 region (PVT1, CCDC26 and GSDMC; Fig. 1a and Extended Data Fig. 1 ) promotes cancer, chromosome engineering 15 (Extended Data Fig. 2 ) was used to derive mice bearing single-copy gain of (1) Myc alone ( Fig. 1b and Extended Data Fig. 2a ), (2) Pvt1, Ccdc26 and Gsdmc ( Fig. 1c and Extended Data Fig. 2b ) and (3) the entire 2-Mb Myc,Pvt1,Ccdc26,Gsdmc syntenic region ( Fig. 1d and Extended Data Fig. 2c ). All three strains were viable and fertile and showed no overt developmental defect. In human breast and ovarian cancers, gain of 8q24 is often accompanied by ERBB2 amplification 16, 17 . Accordingly, each mutant line was bred to MMTVneu transgenic mice 18 and mammary tumour latency was examined. gain(Myc),MMTVneu mice developed mammary tumours at essentially the same median latency (345 days) as MMTVneu mice (Fig. 1e ), indicating that a single supernumerary Myc gene is insufficient to promote MMTVneu-driven cancer. Tumour latency of gain(Pvt1,Ccdc26,Gsdmc),MMTVneu mice was also indistinguishable from MMTVneu mice (316 days; Fig. 1e ). In contrast, gain(Myc,Pvt1,Ccdc26,Gsdmc),MMTVneu mice showed shorter mammary tumour latency (224 days; Fig. 1e ) and increased penetrance (90%) compared with the other three genotypes (40-60%). Compared with age-matched MMTVneu adenomas, gain(Myc,Pvt1,Ccdc26,Gsdmc), MMTVneu tumours presented a high mitotic index involving locally invasive solid masses that invaded adjacent thin-walled blood vessels, consistent with adenocarcinomas (Extended Data Fig. 3a-c) . Three out of ten gain(Myc,Pvt1,Cdc26,Gsdmc) mice, but none of gain(Myc), gain (Pvt1,Cdc26,Gsdmc) and wild-type mice (n 5 10 for each genotype), developed metastasis in the absence of MMTVneu in a limited-lifespan study (500 days), indicating that gain(Myc,Pvt1,Cdc26,Gsdmc) contributes to spontaneous metastasis in older mice, albeit with low penetrance (Extended Data Fig. 3d, e ). These data demonstrate that gain of a single copy of Myc cooperates with one or more genetic element(s) in the Pvt1/Ccdc26/Gsdmc region to promote mammary tumorigenesis.
The mammary epithelium of 10-week-old gain(Myc,Pvt1,Ccdc26,Gsdmc) mice showed pre-cancerous properties in the absence of MMTVneu, including elevated levels of c-H2AX (a marker of DNA damage; Fig. 2a ), p53 (a key mediator of cellular stress response) and phospho-ERK1/2 (a pro-survival signalling molecule; Extended Data Fig. 4a, b) . Accordingly, gain(Myc,Pvt1,Ccdc26,Gsdmc) mammary epithelium showed increased DNA replication (Fig. 2b) , reduced oestrogen receptor-a expression 19 (Extended Data Fig. 4c ) and 5.5 times more lateral ductal branching than wild type (Fig. 2c) . gain(Myc) glands showed a more modest twofold increase in branching compared with wild type. Furthermore, gain(Myc,Pvt1,Ccdc26,Gsdmc) mice showed aberrant differentiation, including a precocious alveolar-like phenotype and co-expression of keratin-14 (a myoepithelial marker) with keratin-8, in luminal epithelial cells (Extended Data Fig. 4d , e). Crossing gain(Myc,Pvt1,Ccdc26, Gsdmc) mice with mice carrying a deletion of precisely the same region resulted in mice with two copies of this region on one chromosome 15 homologue and no copy on the other, which completely abolished aberrant cellular proliferation (Fig. 2d ) and excessive branching (Fig. 2e) . Three copies of the Myc/Pvt1/Ccdc26/Gsdmc region, therefore, produced pre-cancerous phenotypes.
We next sought to identify genetic elements driving gain(Myc,Pvt1, Ccdc26,Gsdmc) neoplasia. Ccdc26 transcript has not been detected in mouse, and Gsdmc expression was low in mouse mammary tissue with no differences in Gsdmc2-4 transcript levels across genotypes (Extended Data Fig. 5 ). Consequently, we focused on Myc and Pvt1. Cells from two independent gain(Myc,Pvt1,Ccdc26,Gsdmc),MMTVneu mammary tumours were transfected with short interfering RNAs (siRNAs) to knockdown Myc (siMyc), Pvt1 (siPvt1) or both, and grown in threedimensional culture. siMyc had no effect on Pvt1 RNA levels, and siPvt1 had no effect on Myc messenger RNA (mRNA) (Fig. 3a) . Depletion of either Myc or Pvt1 RNA resulted in approximately 60% reduction in proliferation as measured by Ki67 staining (Fig. 3b) . Surprisingly, simultaneous knockdown of both Myc and Pvt1 failed to reduce proliferation below individual knockdown of either gene (Fig. 3b) , suggesting that Myc and Pvt1 promote proliferation through the same pathway.
Analysis of Myc and Pvt1 expression showed that both Gain(Myc) and gain(Myc,Pvt1,Ccdc26,Gsdmc) mammary glands showed approximately 3.5-fold more Myc mRNA than wild type or gain(Pvt1,Ccdc26,Gsdmc) (Fig. 3c) . Pvt1 mRNA levels were approximately 1.5 times higher in gain (Pvt1,Ccdc26,Gsdmc) than wild type, as expected, but were surprisingly tenfold elevated in gain(Myc,Pvt1,Ccdc26,Gsdmc) and fourfold increased in gain(Myc) mammary glands (Fig. 3c) . Because MYC protein is a transcriptional activator of PVT1 (refs 20, 21) , this result suggested higher levels of Myc protein and/or activity in gain(Myc,Pvt1,Ccdc26, Gsdmc). Threefold higher Myc protein levels were observed in gain (Myc,Pvt1,Ccdc26,Gsdmc) mammary gland compared with the other three strains (Fig. 3d) . Thus, a third copy of Myc 1 Pvt1 increased Pvt1 transcription and Myc protein in mice.
To extend these findings to high-8q24.21 copy cancers, we examined human breast-cancer cell lines SK-BR-3 and MDA-MB-231, which harbour high copy gains 3 . siMYC and siPVT1 had no effect on PVT1 and MYC RNA, respectively (Fig. 3e ), but reduced proliferation to similar extents with combined siMYC 1 siPVT1 failing to reduce proliferation further (Extended Data Fig. 6a, b) . Furthermore, siPVT1 led to suppression of MYC protein levels (Fig. 3f) , verifying that MYC protein levels are dependent upon PVT1 mRNA in high-copy 8q24-gain cancer cells. Knockdown of individual microRNAs (miRNAs) encoded in the human PVT1 introns had no detectable effect on proliferation (Extended Data Fig. 6c, d) .
The half-life of MYC protein is increased in SK-BR-3 and MDA-MB-231 cells compared with non-transformed breast epithelial cells 22 .
To determine whether MYC protein stability is PVT1-RNA dependent, SK-BR-3 and MDA-MB-231 cells were transfected with siPVT1 or control siRNA and exposed to cycloheximide. PVT1 depletion resulted in more rapid loss of MYC protein than control cells ( Fig. 3g and Extended Data Fig. 7 ). MYC protein degradation is promoted by phosphorylation at threonine 58 (ref. 23) , and mice expressing Myc T58A show enhanced mammary gland density, and mammary carcinoma 24 . Although siPVT1-mediated reduction of MYC protein levels was not accompanied by changes in levels of FBW7 and AXIN1, which are key downstream components of MYC degradation, T58 phosphorylation was increased fivefold (Fig. 3h) . Thus, MYC is protected from phosphorylation at the T58 residue and subsequent degradation in a PVT1-RNA-dependent manner, raising the possibility of a MYC/PVT1 ribonucleoprotein complex. Simultaneous RNA fluorescence in situ hybridization (FISH) to detect PVT1 and immunofluorescence for MYC showed nuclear colocalization in 85.1% of SK-BR-3 cells (Fig. 3i and Extended Data Fig. 8 ). Furthermore, immunoprecipitation using anti-MYC followed by PCR with reverse transcription (RT-PCR) identified PVT1 RNA in the immunoprecipitates (Fig. 3j) , suggesting that PVT1 and MYC physically interact directly or indirectly. Whether specific PVT1 isoform(s), CCDC26 and GSDMC promote malignancy remains to be investigated. Together, these results indicate that gain of the Myc/MYC gene alone fails to increase MYC protein levels but that co-gain of the Pvt1/PVT1 gene disrupts Myc/MYC instability, resulting in increased protein levels and enhanced proliferation.
If PVT1 copy increase is critical for high MYC protein levels, then co-gain of PVT1 should be mandatory in MYC-driven cancer. Analysis Gain Myc 
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of 30,681 tumours from the Progenetix copy-number database showed that 18.8% (5,836 tumours) showed increased 8q24 copy number and 5,763 out of 5,836 of these tumours (98.7%) had increased copy number of both MYC and PVT1 genes. Similarly, analysis of 15,241 tumours from The Cancer Genome Atlas (TCGA) database showed that 18.02% (2,821 tumours) showed 8q24 copy-number increase and that 2,746 out of 2,821 tumours (97.34%) showed co-gain of both MYC and PVT1 whereas fewer than 0.15% of tumours showed increased copy number of MYC but not PVT1 (Fig. 4a and Extended Data Fig. 9a ). Sorting TCGA tumours by cancer type showed differences in the incidence of 8q24 copy-number increase in individual cancer types ranging from MYC 1 PVT1 increase in almost half of ovarian and oesophageal carcinomas to essentially no MYC and/or PVT1 increase among papillary thyroid tumours (Fig. 4b) . Gain of MYC and PVT1 was observed in 62% of 483 HER21 breast cancer samples (Extended Data Fig. 9b ). Unlike mouse, GSDMC orthologues are expressed in human mammary tissue (http://www.genecards.org/cgi-bin/carddisp.pl?gene5GSDMC). Although gain of MYC 1 PVT1 1 CCDC26 1 GSDMC prevailed in low copy-number gain of 8q24 segments, co-gain of MYC 1 PVT1 (but not CCDC26 or GSDMC) prevailed in high copy amplifications (Extended Data Fig. 9c, d ). Co-gain of MYC and PVT1, therefore, dominated over gain of MYC alone across all cancer types showing 8q24 copy-number increases.
To verify these findings, we examined tissue microarrays for PVT1 RNA using in situ hybridization and MYC protein using immunohistochemistry on serial sections of human lung, colon, rectum, stomach, oesophagus, liver, kidney and breast tumours. Concurrent PVT1 RNA and MYC protein expressions were found in all eight cancers ( Fig. 4c and Extended Data Fig. 9e, f) , confirming that PVT1 RNA and the MYC protein are correlated in primary tumours.
Finally, effects of PVT1 loss on MYC-driven tumours were assessed using HCT116 human colorectal carcinoma cells, which harbour low Gain of MYC+PVT1
Gain of PVT1
Gain of MYC n = 1,172 n = 102 n = 803 n = 335 n = 736 n = 132 n = 579 n = 1,031 n = 15 n = 216 n = 110 n = 100 n = 1,022 n = 443 n = 434 n = 34 n = 400 n = 856 n = 335 n = 1,910 n = 269 n = 315 n = 1,037 n = 1,009 n = 1,036 50 
Exon 8 The insets are 33 magnification of the areas marked in each plate. Quantification of the respective colonies (bottom, n 5 3). g, Tumour volume measurements from xenograft transplants of PVT11 and DPVT1 HCT116 cells. Bioluminescent imaging at 3, 7, 10, 13 and 17 days after inoculation (left). DPVT1 HCT116 inoculation at the left flank where the tumour failed to grow is designated by white circle (dashed). Mean tumour volumes are quantified (n 5 6) (right). h, Western blot of MYC and GAPDH protein in three PVT11 and DPVT1 HCT116 clones. Quantification of relative MYC protein levels in PVT11 and PVT1D HCT116 cells is shown (n 5 3). i, Predicted outlook for an 8q24 cancer patient after inhibition of PVT1. Results are shown as mean 6 s.e.m. (*P , 0.05, **P , 0.01, ***P , 0.001, two-tailed Student's t-test). Scale bar, 500 mm (c, top two rows of panels), 50 mm (c, bottom two rows of panels); error bars, s.e.m. (Fig. 4d) 
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copy-number 8q24 gain and stable mutant b-catenin leading to MYC overexpression
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. CRISPR-associated nuclease (Cas9) was used to excise precisely all copies of the PVT1 gene ( Fig. 4e and Extended Data Fig. 10a, b) generating PVT1-null (DPVT1) HCT116 cell lines (Extended Data Fig. 10c ). DPVT1 lines demonstrated reduced proliferation (Extended Data Fig. 10d ) and impaired colony formation in soft agar compared with PVT11 HCT116 cells (232. Fig. 4f) . In xenograft studies, DPVT1 HCT116 cells either failed to form tumours (three out of six xenografts; Fig. 4g ) or showed markedly reduced volume (three out of six xenografts; Extended Data Fig. 10e ) compared with PVT11 counterparts (Fig. 4g) . Finally, MYC protein was significantly reduced (49.1% 6 3.4) in DPVT1 HCT116 clones compared with PVT11 HCT116 cells (Fig. 4h) . PVT1 therefore regulates MYC protein level, and bestows tumorigenic potential to an MYC-driven non-breast cancer line.
Targeting MYC directly with therapeutic interventions has proved challenging [26] [27] [28] ; thus regulation of high MYC protein levels by the PVT1 long non-coding (lncRNA) bears considerable implications for therapeutic treatment of MYC-driven cancers. Because MYC is an important transcription factor and an essential protein 27 , direct inhibition may have severe effects on patients. Our findings indicate that PVT1 lncRNA increases MYC protein levels in 8q24-gain cancers and that loss of PVT1 RNA reduces MYC protein to more normal levels. PVT1, therefore, may be a more accessible and less deleterious target than MYC itself for curtailing MYC-driven cancers (Fig. 4i) . Future studies on the role of PVT1 on the MYC protein level in cancers without supernumerary 8q24 and illuminating the molecular details of MYC/PVT1 cooperation may lead to rational drug discovery specifically targeting the MYC/PVT1 axis in human cancers.
METHODS SUMMARY
Chromosome engineering on mouse AB2.2 embryonic stem cells was as previously described 29 (Extended Data Fig. 2 ). Mouse mammary glands were analysed as described 30 . Tissue microarray slides of human multiple-organ tumours (BC00119) were obtained from US Biomax. For copy-number analysis of TCGA tumours, data were derived from the Affymetrix Genome Wide Human SNP Array 6.0 platform from the open-access directory of TCGA (https://tcga-data.nci.nih.gov/tcgafiles/ ftp_auth/distro_ftpusers/anonymous/tumor/). CRISPR-mediated DPVT1 HCT116 cells were generated using piggyBac co-transposition enrichment.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Mouse strains and tumour analysis. Correctly targeted df/dp embryonic stem clones were injected into C57BL/6J blastocysts to establish chimaeric mice. The F1 dp/1 progeny generated from chimaera crossed with C57BL/6J were genotyped by PCR and backcrossed three times to FVB/N mice. For tumour analysis, dp/1 mouse strains were crossed with FVB/N-Tg(MMTVneu)202Mul/J transgenic mice (purchased from The Jackson Laboratory) to generate the control (hemizygous MMTVneu) and experimental (gain, hemizygous MMTVneu) animals. After 4 months, these mice were monitored weekly by palpation for tumour induction. Tumours were documented in a double-blinded manner. Animal protocols were approved by the Institutional Animal Care and Use Committee of University of Minnesota and were conducted in accordance with the procedures in the Guide for Care and Use of Laboratory Animals (IACUC code number 1206A16225). We calculated our sample size for a power of 0.80 of a significance level of 0.05 for prespecific effect size. The occurrence of spontaneously developing mammary tumour in a group of MMTVneu transgenic mice was 70% (p c 5 0.7) and we wished to test whether a group of gain(Myc,Pvt1,Ccdc26,Gsdmc),MMTVneu mice could reduce the tumour latency by at least 20% (p e 5 0.20), with a power of 80% and a significance level of 5%. Then d 5 0.5 and C 5 7.85 (formula:
, where q c 5 1 -p c , q e 5 1 -p e and d 5 jp c -p e jb). All animals were included. Each animal was assigned to its cohort as determined by its genotype. The animals were housed randomly and monitored for tumour induction in a double-blinded fashion. The tumour latency study was done in a double-blinded fashion, where the animals were assigned numbers instead of their genotypes. After the tumour study, the numbers were replaced with their respective genotypes. Mammary gland isolation, wholemounts and measurement of mammary ductal branching. Ten-week-old virgin mice were killed for dissecting mammary glands. Mammary glands from at least three mice per genotype were analysed. For the mammary ductal branching studies, inguinal (No. 4) mammary glands were spread out, fixed in 4% paraformaldehyde (Merck) for 2 h, then stained. Images were acquired using Leica Application Suite software on a Leica dissecting microscope and analysed using Adobe Photoshop and ImageJ software. The number of ductal branch points was measured from the 25-mm 2 area near the lymph node of the mammary gland. All experimental mice and control mice were littermates with matching oestrous cycles. Histological analysis and tissue immunofluorescence staining. We analysed paraffin sections of paraformaldehyde-fix (4%) mammary glands and tumours stained with haematoxylin and eosin. For immunofluorescence analyses, 5-mm sections were de-paraffinized and rehydrated, and antigens were retrieved using the Antigen Unmasking Solution (Vector Laboratories). Section samples were washed with PBS and blocked using M.O.M. Basic Kit (Vector Laboratories) or 10% normal goat serum for 1 h. Primary antibodies were incubated for overnight at 4 uC. For proliferation assays, mice were injected with 100 mg kg 21 BrdU drug (Sigma) 2 h before being killed, tissues were stained with anti-BrdU (Abcam, ab1893) at 1:300 dilution as described previously 31 and sections were counterstained with DAPI (Invitrogen). Other primary antibodies were diluted with M.O.M. diluent using the following conditions: cytokeratin 8 (1:100, Epitomics, 2032-1), cytokeratin 14 (1:150, Covance, PRB-155P), oestrogen receptor alpha (ERa) (1:50, Santa Cluz Biotechnology, sc-542) and c-H2AX (1:100, Cell Signaling, 2577). Each staining was performed in mammary gland sections dissected from at least three mice of experimental groups and the control group. Fluorescent images were acquired using fluorescence microscopy (Carl Zeiss Axio Obersever.Z1). Cell culture and reagents. Primary mouse tumour cells or primary mouse mammary epithelial cells were dissociated from mammary tumours or mammary glands by incubation with collagenase type I (Invitrogen) for 3 h and then plated on fetuin (Sigma) in growth media (DMEM/F12 containing 10% fetal bovine serum (FBS, Gibco), 5 mg ml 21 insulin (Sigma), 1 mg ml 21 hydrocortisone (Sigma), 5 ng ml 21 EGF (Sigma) and 200 U ml 21 penicillin/streptomycin (Invitrogen)) as described previously 30 . After 3 days, mammary epithelial cells and tumour cells were collected and stored at 280 uC for further experiments. Only early passages of tumour cells were used for advanced assays. Human breast cancer cell lines SK-BR-3 and MDA-MB-231 were obtained from the American Type Culture Collection. SK-BR-3 was short tandem repeat profiled (https://www.atcc.org/Products/All/HTB-30.aspx# A7931A04156C4C7FA40828AEF707302F) and Mycoplasma tested. MDA-MB-231 was also short tandem repeat profiled and Mycoplasma tested (https://www.atcc.org/ Products/All/HTB-26.aspx#A7931A04156C4C7FA40828AEF707302F) SK-BR-3 and MDA-MB-231 cells were cultured in McCoys5A (Lonza) containing 10% FBS and DMEM (Invitrogen) containing 10% FBS respectively. Human colorectal cancer cell line HCT116 was a gift from D. Largaespada. These cells were cultured in ATCC-formulated McCoy's 5a Medium Modified (catalogue number supplemented with 10% FBS. RNA isolation, reverse transcription and RT-qPCR analysis. Mouse mammary glands were removed at 6 and 10 weeks of age and immediately stored in the liquid nitrogen. Frozen mammary tissue lysates were prepared in Trizol Reagent (Invitrogen) by using the SHREDDER SG3 system (Pressure BioSciences) as described by the manufacturer. Cell lysates were collected from six-well plates. RNA was isolated from the Trizol Reagent (Invitrogen), including a DNase digestion step (Qiagen), as described by the manufacturer. Total RNA was quantified by NanoDrop (Thermo Fisher). RNA quality was estimated by running RNA on agarose gels. Complementary DNA (cDNA) was synthesized from equal amounts of total RNA and followed the manufacturer's protocol using SuperScript III reverse transcriptase (Invitrogen) with Random Hexamer primers. For qPCR, the 50 ng of cDNA was added in reactions performed on an ep realplex S machine (Eppendorf) using SYBR Green Master Mix (Promega) and gene-specific primers (Supplementary Table 4) . Primers for all amplification were designed the location on exon-exon borders by using Primer3 software. We used melting curve analysis to confirm the specificity of primers. Amplifications were done as technical duplicates and biological triplicates in 96-well plates. Western blot analysis. Mouse mammary tissues were collected as above and protein extracted by using the SHREDDER SG3 system (Pressure BioSciences) in RIPA lysis buffer (50 mM Tris-HCl pH 7.5; 150 mM NaCl; 1 mM EDTA; 1% Triton-X-100; 0.5% sodium deoxycholate; 0.1% SDS) with Complete Protease Inhibitor Cocktail (Roche Applied Science). Cell lysates were also prepared in RIPA buffer at the indicated time points. Lysates were centrifuged at 18,620g at 4 uC for 30 min, supernatants were collected, and protein was quantified with a Bio-Rad protein assay kit. Equal amounts of protein were loaded and analysed by SDS-polyacrylamide gel electrophoresis. Immunoblotting was done using the following 5 cells were plated to each well of a six-well plate 24 h before the transfection procedure; the cell confluency of each well was 50%. siRNA transfection was applied with DharmaFECT 4 (Thermo Scientific) following the manufacturer's protocol. Cells were collected for RNA isolation 48 h after transfection and for protein extraction 72 h after transfection. siRNA (5 mM) was tranfected into cells. Each experiment was repeated at least three times. For the Ki67 proliferation assay, cells were trypsinized from the well of a six-well plate 24 h after transfection, and 1 3 10 4 cells were re-plated in the three-dimensional on-top culture system to grow for 72 h. For the three-dimensional culture procedure, a total 1 3 10 4 cells were plated on growth-factor reduced matrigel (BD Bioscience) in the eight-well chamber slide as described previously 32 . Mouse mammary epithelial cells were maintained in growth media with 2% matrigel for observing the morphology and measuring the size of acinus-like structures. Ki67 proliferation assay. We performed cell proliferation assays in breast cancer cell lines as previously described 33 . In brief, cells were directly fixed in eight-well chamber slides with 4% paraformaldehyde after siRNA treatments for 96 h. Cells were blocked and stained with Ki67 antibody (1:500, Vector Laboratories) and then counterstained with DAPI for the total number of cells as described previously 32 . Ki67 index was assessed by counting the proportion of Ki67-positive cells. The number of Ki67-positive cells was scored by eye and divided by the total number of cells. The number of total nuclei counted per well was above 500 for each experimental assay. Double fluorescent detection of MYC protein and PVT1 mRNA in SK-BR-3 cells. SK-BR-3 cells were fixed with 4% paraformaldehyde overnight, washed with PBS and then dehydrated. After rehydration, in situ hybridization was performed with fluorescein-labelled PVT1 probe (cDNA clone IMAGE:5517530, Open Biosystems) according to a standard procedure 34 , followed by goat anti-MYC antibody (AF3696, 10 mg ml
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, R&D Systems) reaction at 4 uC overnight. The samples were treated with Alexa Fluor 594 anti-Fluorescein/Oregon Green (Invitrogen; A11091, 1:100) and Alexa Fluor 488 anti-goat IgG (Invitrogen; A11055, 1:1,000), and counterstained with DAPI. Fluorescent signals were detected using a Zeiss LSM 710 laser scanning microscope system (Carl Zeiss Microscopy) and analysed by ZEN2009 software (Carl Zeiss Microscopy). Because the sense PVT1 probe detected some nuclear signal, albeit much weaker than the antisense probe, it is possible that the observed PVT1 FISH staining could have contained some non-specific nuclear staining.
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Tissue microarray analysis. Human multiple organ tumour tissue microarray slides (BC00119) were obtained from US Biomax. In situ hybridization used digoxigeninlabelled PVT1
34 probe according to a standard procedure 34 and counterstaining with nuclear fast red. MYC immunohistochemistry was done using anti-MYC antibodies HRP-conjugated rabbit anti-goat IgG (Bio-Rad, 172-1034, 1:500), and visualized by a peroxidase substrate kit (Vector Laboratories, SK-4105). RNA-immunoprecipitation analysis. RNA-immunoprecipitation analysis using anti-MYC or preimmune IgG (negative control) antibody was performed as described before 35 using Immunoprecipitation Kit Dynabeads Protein G (Invitrogen). Twenty million SK-BR-3 cells were used to generate 2-5 mg of total protein per RNAimmunoprecipitation. MYC and PVT1 gain across human cancers. Copy-number gain of MYC, PVT1 or MYC 1 PVT1 in human tumours was assessed by examining the copy-number data from the TCGA and Progenetix genomic copy-number aberration databases. For TCGA, the copy-number variation results (level 3) derived from Affymetrix Genome Wide Human SNP Array 6.0 platform for 15,888 tumour samples were downloaded from TCGA's open-access HTTP directory (https://tcga-data.nci.nih. gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/). For Progenetix, the chromosomal regions with copy-number aberration derived from chromosomal comparative genomic hybridization and array comparative genomic hybridization for 30,681 tumour samples were downloaded from the Progeneix website (http://www. progenetix.org/). For each sample, we cross-compared the loci of three MYC exons , with chromosomal regions having copy gains. For TCGA, segmentation mean value was greater than 0.22; and for chromosomal comparative genomic hybridization and array comparative genomic hybridization data from Progenetix, the regions with segvalue 1 were considered as copy gains. Overlapped exon(s) were recorded. Co-gain of MYC 1 PVT1 1 CCDC26 1 GSDMC in low versus high copy-number gain of 8q24. We investigated the relationship between ratio of MYC 1 PVT1 1 CCDC26 or MYC 1 PVT1 1 GSDMC co-amplification on MYC 1 PVT1 coamplification at different amplification levels on TCGA data. The level 3 copynumber variation data from TCGA provided a log-ratio-based mean copy-number estimate of segments covering genomic regions (inferred from the Affymetrix Genome Wide Human SNP Array 6.0 platform). We used segment mean 0.32 (2.5 copies) as a cutoff for copy gains. The Progenetix database did not provide such a distinction between amplification levels. Generating DPVT1 HCT116 cells. The human-codon-optimized Cas9 cDNA and chimaeric guide RNA (gRNA) were acquired from Addgene (41815 and 41824). Cas9 was PCR amplified and cloned into pENTR221 using SnaBI and XbaI sites engineered into the PCR primers. pENTR221 was then transferred to pT3.5-CAG-DEST by standard LR Clonase (Invitrogen) reaction, following the manufacturer's instructions. The chimaeric gRNA was PCR amplified and cloned into pENTR221 using SnaBI and XbaI. gRNAs targeting the 59 and 39 ends of PVT1 were designed using Zfit software (http://zifit.partners.org/ZiFiT/). gRNAs targeting PVT1 were generated using inverse PCR of pENTR221-gRNA using the common reverse primer 59-CGGTGTTTCGTCCTTTCCAC-39, and target specific forward primer for the 59 end (59-CATCACCGGGGATTCCCTCGTTTTAGAGCTAGAAATA GC-39) and 39 end (59-GCCTGGAGGCCAGCTCAAAGTTTTAGAGCTAGAA ATAGC-39) of PVT1 using Accuprime Pfx Supermix (Invitrogen), following the manufacturer's instructions. Purified PCR products were then treated with polynucleotide kinase and T4 Ligase (New England Biolabs), following the manufacturer's instructions. New gRNAs were sequence verified by standard Sanger sequencing.
CRISPR-mediated DPVT1 HCT116 cells were then generated using piggyBac co-transposition enrichment as described 36 . Briefly, cells were NEON electroporated with 2 mg each of hCas9 and the 59 and 39 PVT1 gRNA in addition to the 500 ng each of PB7 transposase and PB-CAG-Luc (puro) transposon vector. CRISPR treated cells were then incubated at 37 uC for 3 days. Cells were then seeded at varying densities (100-1000 cells per well) in 96-well plates with Puromycin containing DMEM media. Wells that produced single colonies were expanded and DNA extracted. Clones were then genotyped for deletion of PVT1 using standard PCR genotyping (primer sequences are provided). Identified wild-type clones were used as controls. Proliferation, soft agar and xenograft assay for PVT11 and DPVT1 HCT116 cells. The proliferation assay used CellTiter 96 AQ ueous One Solution Cell Proliferation Assay (MTS) (Promega G3580) according to the manufacturer's instructions. Two thousand cells were seeded per well. Three independent clones for each genotype were used for the study in triplicate (n 5 3).
Soft agar and xenograft assays for PVT11 and DPVT1 HCT116 cells were performed using established protocol 37 . For the soft-agar anchorage-independent colony-formation assay, experiments were performed in triplicate. Three independent clones from each genotype were used. Three thousand cells per plate were seeded in soft agar. Colonies were allowed to grow for 2 weeks and then fixed in 10% formalin containing 0.005% crystal violet for 1 h at 25 uC. After removing formalin, colonies were imaged on a Leica S8 AP0 microscope. Twelve images for each plate were taken and the colonies counted by using ImageJ software.
For xenograft assay, 2 3 10 6 DPVT1 HCT116 and approximately equal numbers of PVT1 1 HCT116 were injected subcutaneously on the left and the right flank of a nude mouse respectively. Six nude mice were used for the study. Tumour growth was monitored on the indicated days by bioluminescence using a Xenogen IVIS spectrum system, after delivering 100 ml of 28.5 mg ml 21 luciferin by intraperitoneal injection. The tumour volumes were measured by using electronic calliper (length 3 width 3 height). Eliminating bias by blinded analysis. All analyses were in a double-blinded fashion. Statistical analysis. For tumour-free survival curves, statistical analyses used Prism 4 (GraphPad Software), and P values were calculated by the log-rank test. All other P values were calculated using Student's t-test (unpaired, two-tailed, P , 0.05 was considered significant). Results are reported as mean 6 s.e.m. or mean 6 s.d. The biological replicates for each experiment are represented in the figure legends. All technical replicates were performed three times. Oligonucleotide sequences. Linker: GsdmcR-linker-F: CGGCCAATGCGGCC GCTATG; GsdmcR-linker-R: CTAGCATAGCGGCCCGCATTGGCCGA; Gene targeting: GsdmcR-5S1: GGAAGAGCGCCCAATACGCAA; GsdmcR-gap-S19: GTAACCGTACCCACTCATGCAA; GsdmcR-5S2: GGACAGTTTCCACCACT GTCAA; GsdmcR-gap-S29: GTGGGTACGGTTACAGTGATGAA; MycL-3S1: A GGCTGCGCAACTGTTGGGAA; MycL-gap-S19: GGAATACTGGTCACATCT GCCTT; MycL-3S2: GTTGCCAGCCATCTGTTGTT; MycL-gap-S29: AGCTTC TCATTTACTAACGGCAA; MycR-3S1: AGGCTGCGCAACTGTTGGGAA; MycRgap-S19: TGAAGCCTGGGCTAGAGATG; MycR-3S2: GTTGCCAGCCATCTG TTGTT; MycR-gap-S29: GGAAGGGGAAGTGGATAGGA; MycL-5S1: GGAA GAGCGCCCAATACGCAA; MycL-gap-S19: GGAATACTGGTCACATCTGC CTT; MycL-5S2: GGACAGTTTCCACCACTGTCAA; MycL-gap-S29: AGCTTC TCATTTACTAACGGCAA; Mouse genotyping: Myc-Gsdmc-dp-F: AACTGGC TGAGTGACGCCCTTTAT; Myc-Gsdmc-dp-R: TGAGACGTGCTACTTCCA TTTGTC; Myc-Gsdmc-df-F: ATCCAGCAGGTCAGCAAAGA; Myc-Gsdmcdf-R: CTGGCGTCGTGATTAGTGATG; Myc-dp-F: ATCCAGCAGGTCAGCA AAGA; Myc-dp-R: CTGGCGTCGTGATTAGTGATG; Pvt1-Gsdmc-dp-F: AAC TGGCTGAGTGACGCCCTTTAT; Pvt1-Gsdmc-dp-R: TGAGACGTGCTACT TCCATTTGTC; qPCR: Mus-Myc- ) or puromycine (P, 3 mg ml
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) for 7-10 days. Correctly targeted clones were identified by PCR analysis. Double-targeted embryonic stem cells were electroporated with the transient Cre-recombinase expression vector pOG231. After subsequent selection of recombinants by using hypoxanthine aminopterin thymidime (H) media for 7 days and then recovery of recombinants by using hypoxanthines and thymidine media for 2 days, the H R G R P R clones containing one mouse chromosome 15 with the targeted region duplication (dp) and the other mouse chromosome 15 with the targeted region deletion (df) were identified. d, Summary of gene targeting of mouse genome at the MycL, MycR and GsdmcR loci. e, FISH analysis of gain/loss Myc,Pvt1,Ccdc26,Gsdmc embryonic stem cells with balanced allele for the Myc/Pvt1/Ccdc26/Gsdmc region. Metaphase and interphase preparations from the engineered cells were probed with BAC clone specific for chromosome 15 and located outside (RP23-18H8, red) and within (RP24-78D24, green) the engineered region. The alleles containing the deletion and the duplication are marked.
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Extended Data Figure 4 | Abnormal oncogenic stress, proliferation and differentiation in gain(Myc,Pvt1,Ccdc26, Gsdmc) mammary ducts. a, b, Western blot analysis of p53 (a) and phospho-Erk1/2 (b) in total protein lysates from mammary glands of indicated genotypes. The relative densities of p53 and p-ERK1/2 were calculated by normalizing against the GAPDH and total ERK1/2 protein levels respectively. c, Immunofluorescence analysis of ERa (green) on sections of mammary ducts. Cell nuclei positive for ERa are presented as the percentage of total epithelial cell nuclei (DAPI, blue). Images shown are representative three mice per genotype. d, Haematoxylin and eosin staining of the mammary ducts from wild type and gain (M,P,C,G) mice showed precocious alveolar-like phenotype in the latter. This aberrant structure is shown at higher magnification in the right row. e, Immunofluorescence co-staining for DAPI (blue), luminal marker K8 (red) and myoepithelial marker K14 (green) in mice. Arrowheads indicate co-expression of K8 and K14. DAPI-stained nuclei in blue. Mean 6 s.e.m. for a-c (n 5 3). *P , 0.05, ***P , 0.001 by two-tailed Student's t-test; error bars, s.e.m. LETTER RESEARCH
